Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Mexico City, 14080, Mexico
NCT Number: NCT05200468
The benefits of nutritional interventions with dietary restrictions are associated with improvement and preservation of mitochondrial function. Evidence suggests that dietary restrictions, including modifications in caloric intake (caloric restriction), or in the timing of food intake (e.g., intermittent fasting), play an important role in stimulating cell and mitochondrial autophagy, favoring the elimination of old and dysfunctional mitochondria. In addition to the observed effects on mitochondrial function, there is evidence that intermittent fasting, caloric restriction, and the ketogenic diet also generate changes in gut microbiota and microbial metabolite composition. The main aim of this study is to evaluate the effect of intermittent fasting, caloric restriction and ketogenic diet on mitochondrial function determined by respirometry in monocytes, modulated by the gut microbiota in subjects with obesity. An open randomized controlled clinical trial will be conducted with 80 participants divided by a draw in 4 nutritional interventions groups for 1 month, each for 20 participants, then participants will receive 550 mg of rifaximin and will finish the study with the assigned nutritional intervention for another month of follow-up. Knowledge of these dynamics will allow us to explore and understand the relationship between metabolites from the gut microbiota and their effect on mitochondrial function associated with the dietary interventions mentioned above.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Not applicable
Mexico City, 14080, Mexico
The study consists of an open-label randomized controlled clinical trial. Selected subjects will be randomized to one of 4 dietary intervention groups for 1 month with energy intake according to the resting energy expenditure obtained by indirect calorimetry.
The intervention groups will be as follows; a) ketogenic diet, b) caloric restriction diet, c) intermittent fasting diet and, d) usual diet.
After one month of the assigned intervention, the antibiotic rifaximin will be prescribed to the participants in doses of 550mg, twice a day for 7 days. After the 7 days with the antibiotic, participants will complete another month with the dietary intervention according to the group that the participants were initially randomized.
Participants will be required to complete food logs (2 on weekdays and 1 for weekends) during each week in order to monitor adherence to the dietary plan. For this, a nutritionist will teach them how to complete the food log, where participants must record the type, quantity and place where the food was consumed at each feeding time. Also, 2 phone calls will be made each week to evaluate adherence to treatment. The adherence will be determined with the % of adherence to the dietary treatment as obtained in the analysis of the food logs. Similarly, urine ketone concentration will be determined to measure adherence to the ketogenic diet. A logbook will be provided by the investigator to the participants to record the consumption of the medication, which should be filled out daily by the participant.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Weekly menus will be delivered according to diet with the following macronutrient distribution: 25% protein, 10% carbohydrate, 65% fat. Participants will receive a 30-day food menu guide.
Weekly menus will be provided according to their usual diet with 500 kcal restriction with the following macronutrient distribution 25-35% protein, 45-55% carbohydrates, 20-30% fat. Participants will receive a 30-day food menu guide.
Calorie-restricted menus will be provided with a 16:8 time-restricted feeding. The feeding window will be 8 hours with a fasting time of 16 hours (04.00 pm- 08.00 am or 05.00 pm - 09.00 am), during the fasting window participants will only be allowed to drink water, unsweetened tea, mineral water and coffee without added sugar. Participants will receive a 30-day food menu guide.
Time frame: Baseline to 4, 5 and 8 weeks
Change in mitochondrial function determined by mitochondrial oxygen consumption rate in monocytes
Time frame: Baseline to 4, 5 and 8 weeks
Change in microbiota composition determined by alpha and beta diversity analysis to compare the baseline and final microbiota composition between different nutritional interventions in subjects with obesity.
Time frame: Baseline to 4, 5 and 8 weeks
Change in markers of oxidative stress determined by levels of malondialdehyde and reactive oxygen species to compare the baseline and final markers of oxidative stress between different nutritional interventions in subjects with obesity.
Time frame: Baseline to 4, 5 and 8 weeks
Change in body composition determined by multifrequency electrical bioimpedance to compare the baseline and final fat mass, lean mass and skeletal muscle mass percentage between different nutritional interventions in subjects with obesity
Time frame: Baseline to 4, 5 and 8 weeks
Change in body weight to compare the baseline and final body weight between different nutritional interventions in subjects with obesity
Time frame: Baseline to 4 and 8 weeks
Change in grip strength determined by dynamometry to compare the baseline and final grip strength between different nutritional interventions in subjects with obesity.
Time frame: Baseline to 4 and 8 weeks
Change in glucose in the serum determined by autoanalyzer to compare the baseline and final concentration of serum glucose between different nutritional interventions in subjects with obesity.
Time frame: Baseline to 4 and 8 weeks
Change in total cholesterol in the serum by autoanalyzer to compare the baseline and final concentration of serum total cholesterol between different nutritional interventions in subjects with obesity
Time frame: Baseline to 4 and 8 weeks
Change in HDL cholesterol serum by autoanalyzer to compare the baseline and final concentration of serum HDL-cholesterol between different nutritional interventions in subjects with obesity.
Time frame: Baseline to 4 and 8 weeks
Change in triglycerides in the serum by autoanalyzer to compare the baseline and final concentration of serum triglycerides between different nutritional interventions in subjects with obesity.
Time frame: Baseline to 4 and 8 weeks
Change in LDL cholesterol in the serum by autoanalyzer to compare the baseline and final concentration of serum LDL cholesterol between different nutritional interventions in subjects with obesity.
Time frame: Baseline to 4 and 8 weeks
Change in leptin concentration in the serum determined by ELISA kit to compare the baseline and final concentration of serum leptin between different nutritional interventions in subjects with obesity.
Time frame: Baseline to 4 and 8 weeks
Change in adiponectin concentration in the serum determined by ELISA kit to compare the baseline and final concentration of serum leptin between different nutritional interventions in subjects with obesity.
Time frame: Baseline to 4 and 8 weeks
Change in C-reactive protein concentration in the serum to compare the baseline and final concentration of serum C- reactive protein between different nutritional interventions in subjects with obesity.
Time frame: Baseline to 4 and 8 weeks
Change in systolic and diastolic blood pressure to compare the baseline and final blood pressure between different nutritional interventions in subjects with obesity.
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Other
Effect of Intermittent Fasting, Caloric Restriction and Ketogenic Diet on Mitochondrial Function and Gut Microbiota in Subjects With Obesity
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05742165
Behavior, Body Weight
New York, United States
View Trial DetailsNCT05882045
Body Weight, Cardiovascular Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT05929079
Apnea, Body Weight
Anniston, Alabama, United States
View Trial DetailsNCT00342732
Body Weight, Nutrition Disorders
Phoenix, Arizona, United States
View Trial Details